Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

toripalimab 1sodium thiosulfate 1naxitamab 1Vincristine 1Rituximab 1Methotrexate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Eflornithine 1Drug Therapy 1Doxorubicin 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Has announcements × naxitamab × Clear all
NCT01757626 2026-01-07

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
186 enrolled 1 FDA
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡